Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

(2017) George D. Demetri et al.   Journal of the National Comprehensive Cancer Network

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors

(2012) Debi Bhattacharya et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia

(2011) Prasanth Ganesan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

(2011) Sofia Jönsson et al.   ANNALS OF HEMATOLOGY

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

(2011) A. R. Ibrahim et al.   BLOOD

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

(2011) Chikashi Yoshida et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Perspectives on Adherence and Persistence With Oral Medications for Cancer Treatment

(2011) John Hohneker et al.   Journal of Oncology Practice

Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors

(2010) Jean-Yves Blay et al.   CANCER

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?

(2010) Margaret von Mehren et al.   CANCER TREATMENT REVIEWS

Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists

(2010) V. REGNIER DENOIS et al.   EUROPEAN JOURNAL OF CANCER CARE

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

(2010) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed

(2010) Lina Eliasson et al.   LEUKEMIA RESEARCH

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) L. Noens et al.   BLOOD

Patient adherence and persistence with oral anticancer treatment

(2009) K. Ruddy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

(2009) Eric Q. Wu et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

(2008) C McCowan et al.   BRITISH JOURNAL OF CANCER

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY